Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Role of the copper transporter, CTR1, in platinum-induced ototoxicity.

More SS, Akil O, Ianculescu AG, Geier EG, Lustig LR, Giacomini KM.

J Neurosci. 2010 Jul 14;30(28):9500-9. doi: 10.1523/JNEUROSCI.1544-10.2010.

2.

Cisplatin ototoxicity in rat cochlear organotypic cultures.

Ding D, He J, Allman BL, Yu D, Jiang H, Seigel GM, Salvi RJ.

Hear Res. 2011 Dec;282(1-2):196-203. doi: 10.1016/j.heares.2011.08.002. Epub 2011 Aug 12.

3.

Transtympanic administration of short interfering (si)RNA for the NOX3 isoform of NADPH oxidase protects against cisplatin-induced hearing loss in the rat.

Mukherjea D, Jajoo S, Kaur T, Sheehan KE, Ramkumar V, Rybak LP.

Antioxid Redox Signal. 2010 Sep 1;13(5):589-98. doi: 10.1089/ars.2010.3110.

4.

Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.

Blair BG, Larson CA, Safaei R, Howell SB.

Clin Cancer Res. 2009 Jul 1;15(13):4312-21. doi: 10.1158/1078-0432.CCR-09-0311. Epub 2009 Jun 9.

5.

Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells.

Blair BG, Larson CA, Adams PL, Abada PB, Safaei R, Howell SB.

Mol Pharmacol. 2010 Jun;77(6):912-21. doi: 10.1124/mol.109.062836. Epub 2010 Mar 1.

6.

Sound preconditioning therapy inhibits ototoxic hearing loss in mice.

Roy S, Ryals MM, Van den Bruele AB, Fitzgerald TS, Cunningham LL.

J Clin Invest. 2013 Nov;123(11):4945-9. Erratum in: J Clin Invest. 2014 Jan 2;124(1):461.

7.

Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells.

Kalayda GV, Wagner CH, Jaehde U.

J Inorg Biochem. 2012 Nov;116:1-10. doi: 10.1016/j.jinorgbio.2012.07.010. Epub 2012 Jul 26.

PMID:
23010323
8.

Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity.

Liu JJ, Jamieson SM, Subramaniam J, Ip V, Jong NN, Mercer JF, McKeage MJ.

Cancer Chemother Pharmacol. 2009 Sep;64(4):847-56. doi: 10.1007/s00280-009-1017-6. Epub 2009 May 24.

PMID:
19466412
9.

Protective effects of apocynin on cisplatin-induced ototoxicity in an auditory cell line and in zebrafish.

Choi J, Im GJ, Chang J, Chae SW, Lee SH, Kwon SY, Chung AY, Park HC, Jung HH.

J Appl Toxicol. 2013 Feb;33(2):125-33. doi: 10.1002/jat.1729. Epub 2011 Dec 6.

PMID:
22147442
10.

The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity.

Pabla N, Murphy RF, Liu K, Dong Z.

Am J Physiol Renal Physiol. 2009 Mar;296(3):F505-11. doi: 10.1152/ajprenal.90545.2008. Epub 2009 Jan 14.

11.

Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.

Shang X, Lin X, Manorek G, Howell SB.

Mol Pharmacol. 2013 Jan;83(1):85-94. doi: 10.1124/mol.112.079798. Epub 2012 Oct 10.

12.

Review: ototoxic characteristics of platinum antitumor drugs.

Ding D, Allman BL, Salvi R.

Anat Rec (Hoboken). 2012 Nov;295(11):1851-67. doi: 10.1002/ar.22577. Epub 2012 Oct 8. Review.

13.

A role for the copper transporter Ctr1 in the synergistic interaction between hyperthermia and cisplatin treatment.

Landon CD, Benjamin SE, Ashcraft KA, Dewhirst MW.

Int J Hyperthermia. 2013 Sep;29(6):528-38. doi: 10.3109/02656736.2013.790563. Epub 2013 Jul 23.

14.

Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions.

Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstädt H, Lanvers-Kaminsky C, am Zehnhoff-Dinnesen A, Schinkel AH, Koepsell H, Jürgens H, Schlatter E.

Am J Pathol. 2010 Mar;176(3):1169-80. doi: 10.2353/ajpath.2010.090610. Epub 2010 Jan 28.

15.

The role of peroxiredoxin I in cisplatin-induced ototoxicity.

Le Q, Tabuchi K, Warabi E, Hara A.

Auris Nasus Larynx. 2017 Apr;44(2):205-212. doi: 10.1016/j.anl.2016.06.001. Epub 2016 Jun 16.

PMID:
27318370
16.

Assessing cisplatin-induced ototoxicity and otoprotection in whole organ culture of the mouse inner ear in simulated microgravity.

Tropitzsch A, Arnold H, Bassiouni M, Müller A, Eckhard A, Müller M, Löwenheim H.

Toxicol Lett. 2014 Jun 16;227(3):203-12. doi: 10.1016/j.toxlet.2014.03.022. Epub 2014 Apr 5.

17.

Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1.

Jandial DD, Farshchi-Heydari S, Larson CA, Elliott GI, Wrasidlo WJ, Howell SB.

Clin Cancer Res. 2009 Jan 15;15(2):553-60. doi: 10.1158/1078-0432.CCR-08-2081.

18.
19.

In vitro and in vivo effects of lutein against cisplatin-induced ototoxicity.

Roldán-Fidalgo A, Martín Saldaña S, Trinidad A, Olmedilla-Alonso B, Rodríguez-Valiente A, García-Berrocal JR, Ramírez-Camacho R.

Exp Toxicol Pathol. 2016 Apr;68(4):197-204. doi: 10.1016/j.etp.2016.01.003. Epub 2016 Feb 2.

PMID:
26850526
20.

Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons.

Liu JJ, Kim Y, Yan F, Ding Q, Ip V, Jong NN, Mercer JF, McKeage MJ.

Biochem Pharmacol. 2013 Jan 15;85(2):207-15. doi: 10.1016/j.bcp.2012.10.023. Epub 2012 Nov 1.

PMID:
23123662

Supplemental Content

Support Center